Clopidogrel is an anticoagulant forming part of the class of drugs known as platelet aggregation inhibitors. These drugs make it more difficult for platelets to clump together, reducing the risk of blood clots developing (thrombosis). Clopidogrel is prescribed following a heart attack or stroke or to treat angina (heart spasm), but also after an angioplasty procedure or the insertion of a stent.
Clopidogrel and the benefit of DNA analysis
The rate at which clopidogrel is metabolised within your body into an active component varies from one individual to another. This means that the efficacy and side effects of clopidogrel can be predicted to some extent on the basis of your genes. Preventive DNA analysis can therefore be an important tool in optimising your medication.
Clopidogrel and the enzyme CYP2C19
Clopidogrel is a drug that first needs to be metabolised into an active component within the body. The enzyme CYP2C19 plays an important role in this process.
The activity of this enzyme can, however, vary considerably depending on your genetic predisposition, which means the availability of the active component of clopidogrel can also differ from person to person.
Information about your genetic predisposition may therefore provide grounds to opt for an alternative anticoagulant.
Read more about CYP2C19 enzyme »
Also known as
Plavix, Duoplavin, Grepid, clopidogrel, clopidogrelum